110 related articles for article (PubMed ID: 16125569)
1. T-cell depletion to prevent GVHD after unrelated-donor marrow transplantation.
Locatelli F; De Stefano P
Lancet; 2005 Aug 27-Sep 2; 366(9487):692-4. PubMed ID: 16125569
[No Abstract] [Full Text] [Related]
2. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial.
Wagner JE; Thompson JS; Carter SL; Kernan NA;
Lancet; 2005 Aug 27-Sep 2; 366(9487):733-41. PubMed ID: 16125590
[TBL] [Abstract][Full Text] [Related]
3. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation.
Champlin R
Hematol Oncol Clin North Am; 1990 Jun; 4(3):687-98. PubMed ID: 2193019
[TBL] [Abstract][Full Text] [Related]
4. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
[TBL] [Abstract][Full Text] [Related]
5. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
Gadisseur AP; Gratama JW; Lamers C; van Esser JW; Bolhuis RL; Cornelissen JJ
Bone Marrow Transplant; 1999 May; 23(10):1013-7. PubMed ID: 10373067
[TBL] [Abstract][Full Text] [Related]
6. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
7. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
8. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
Hale G; Waldmann H
Bone Marrow Transplant; 1994 May; 13(5):597-611. PubMed ID: 8054913
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-leukemia activity after T-cell depletion using counterflow centrifugation.
de Witte T; Preijers F; Schattenberg A
Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():103-5. PubMed ID: 2202463
[No Abstract] [Full Text] [Related]
11. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
[TBL] [Abstract][Full Text] [Related]
12. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
Johnson BD; Drobyski WR; Truitt RL
Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
[TBL] [Abstract][Full Text] [Related]
13. Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease.
Ho VT; Kim HT; Li S; Hochberg EP; Cutler C; Lee SJ; Fisher DC; Milford E; Kao G; Daley H; Levin J; Ng A; Mauch P; Alyea EP; Antin JH; Soiffer RJ
Bone Marrow Transplant; 2004 Dec; 34(11):987-94. PubMed ID: 15489873
[TBL] [Abstract][Full Text] [Related]
14. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
15. Perspectives in marrow graft T-cell depletion in allogeneic matched related bone marrow transplantation.
Tiberghien P; Hervé P
Transfus Sci; 1992; 13(4):443-54. PubMed ID: 10147740
[No Abstract] [Full Text] [Related]
16. T cell depletion in bone marrow transplantation for leukemia: current results and future directions.
Butturini A; Gale RP
Bone Marrow Transplant; 1988 May; 3(3):185-92. PubMed ID: 3048485
[TBL] [Abstract][Full Text] [Related]
17. [Prevention of graft versus host disease by in vitro depletion of T lymphocytes with monoclonal antibodies (Campath-1) in patients undergoing bone marrow transplantation].
Iriondo A; Richard C; Hermosa V; Conde E; Garijo J; Cuadrado MA; Bello C; Muruzábal MJ; Pérez-Encinas M; Zubizarreta A
Med Clin (Barc); 1988 Oct; 91(13):488-92. PubMed ID: 3067007
[No Abstract] [Full Text] [Related]
18. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
[TBL] [Abstract][Full Text] [Related]
19. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
[TBL] [Abstract][Full Text] [Related]
20. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow.
Truitt RL; Atasoylu AA
Bone Marrow Transplant; 1991 Jul; 8(1):51-8. PubMed ID: 1833016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
